^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PSMA-targeted antibody-drug conjugate

    Related drugs:
    10d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=183, Active, not recruiting, Janssen Research & Development, LLC | N=50 --> 183
    Enrollment change • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    14d
    A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=180, Recruiting, T.O.A.D. Oncology SA | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    FOLH1 expression
    17d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=183 --> 50 | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    18d
    TD001-101: A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA protein. (2025-523273-41-00)
    P1/2, N=110, Recruiting, T.O.A.D. Oncology S.A.
    New P1/2 trial • First-in-human
    |
    HRD (Homologous Recombination Deficiency)
    22d
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> Mar 2027 | Trial primary completion date: Sep 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    2ms
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    3ms
    A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, T.O.A.D. Oncology SA
    New P1/2 trial
    3ms
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P1 trial • First-in-human
    4ms
    An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients with Advanced Solid Tumors. (ChiCTR2500110610)
    P1, N=150, Not yet recruiting, Zhejiang Cancer Hospital; Hangzhou DAC Biotechnology Co.,Ltd.
    New P1 trial • First-in-human
    5ms
    A Study of MHB048C in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P1/2 trial
    6ms
    A Study of DXC014 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Hangzhou DAC Biotechnology Co., Ltd.
    New P1 trial • First-in-human
    6ms
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1, N=110, Recruiting, Hangzhou DAC Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open